Jean Gabriel de Souza

TL;DR: The use of these cells as a therapeutic carrier strategy to target GBM cells must be approached with caution, as it is observed that, after infiltrating the tumor, MSCs promote tumor growth in vivo probably by release of exosomes.

TL;DR: It was shown that Amblyomin-X, a Kunitz-type inhibitor identified in the transcriptome of the Amblyomma cajennense tick by ESTs sequence analysis of a cDNA library, induces apoptosis in murine renal adenocarcinoma (RENCA) cells by inducing imbalance between pro- and anti-apoptotic Bcl-2 family proteins, dysfunction/mitochondrial damage, and production of reactive oxygen species (ROS).

TL;DR: The in vitro assays show that Amblyomin-X is capable of reducing the proliferation rate of Renca cells, promoting cell cycle arrest, and down-regulating the expression of crucial proteins involved in the aggressiveness and resistance of RCC.

TL;DR: The findings presented in this review strongly suggest Amblyomin-X as a promising novel antitumor drug candidate as well as biodiversity and bioprospection reasons.

TL;DR: It was found that the CD133+ glioblastoma cells expressed both the pluripotency stem cell markers (Nanog, Mush-1 and SSEA-3) and MSC markers, and were able to differentiate into adipocyte-like cells, thus possibly enabling differentiation into both neural and mesodermal cell types.